K. Combrink

发表

C25-modified rifamycin derivatives with improved activity against Mycobacterium abscessus

H. Rohde, M. Aepfelbacher, B. Aldridge, 2021, bioRxiv.

Rifamycin derivatives active against pathogenic rapidly-growing mycobacteria.

S. Schmidl, P. Morin, F. Maurer, 2019, Bioorganic & medicinal chemistry letters.

Respiratory syncytial virus fusion inhibitors. Part 6: an examination of the effect of structural variation of the benzimidazol-2-one heterocycle moiety.

N. Meanwell, D. Langley, I. Medina, 2007, Bioorganic & medicinal chemistry letters.

Respiratory syncytial virus fusion inhibitors. Part 5: Optimization of benzimidazole substitution patterns towards derivatives with improved activity.

N. Meanwell, D. Langley, C. Cianci, 2007, Bioorganic & medicinal chemistry letters.

Respiratory syncytial virus fusion inhibitors. Part 3: Water-soluble benzimidazol-2-one derivatives with antiviral activity in vivo.

N. Meanwell, I. Medina, C. Cianci, 2006, Bioorganic & medicinal chemistry letters.

Respiratory syncytial virus inhibitors. Part 2: Benzimidazol-2-one derivatives.

N. Meanwell, C. Cianci, M. Krystal, 2004, Bioorganic & medicinal chemistry letters.

Stereoselective 3 + 2 and stereospecific 2 + 2 cycloaddition reactions of alkenes and quinones

T. Engler, J. Ray, K. Combrink, 1988 .

Adsorption and Removal of Thymol from Water Using a Zeolite Imidazolate Framework-8 Nanomaterial

D. Ganta, C. Guzmán, K. Combrink, 2020, Analytical Letters.

Rho-Rho kinase pathway in the actomyosin contraction and cell-matrix adhesion in immortalized human trabecular meshwork cells

S. P. Srinivas, N. Sharif, R. Patil, 2011, Molecular vision.

An Enantioselective Approach to the Taxanes: Direct access to functionalized cis‐tricyclo[9.3.1.03,8]pentadecanes via α‐hydroxy ketone and Wagner‐Meerwein rearrangements

S. Elmore, R. Rogers, L. Paquette, 1992 .

Setting the Bridgehead Oxidation Level in trans‐Tricyclo[9.3.1.03,8]pentadecanes as a Prelude to the Dual Synthesis of Taxol and Taxusin

S. Elmore, L. Paquette, K. Combrink, 1992 .

A convenient means for controlling the oxidation level of bridgehead carbon C-1 in functionalized tricyclo[9.3.1.03,8]pentadecanes

S. Elmore, L. Paquette, K. Combrink, 1991 .

Impact of substituent modifications on the atropselectivity characteristics of an anionic oxy-Cope ring expansion

S. Elmore, R. Rogers, L. Paquette, 1991 .

Synthesis and antibacterial evaluation of a novel series of rifabutin-like spirorifamycins.

T. Morris, D. Yan, P. Renick, 2007, Bioorganic & medicinal chemistry letters.

Formal 2+2 and 3+2 cycloaddition reactions of 2H-chromenes with 2-alkoxy-1,4-benzoquinones: regioselective synthesis of substituted pterocarpans

T. Engler, D. Velde, J. Reddy, 1990 .

Discovery and early clinical evaluation of BMS-605339, a potent and orally efficacious tripeptidic acylsulfonamide NS3 protease inhibitor for the treatment of hepatitis C virus infection.

A. Good, H. Klei, A. Cocuzza, 2014, Journal of medicinal chemistry.

Structure-based design and optimization of potent inhibitors of the adenoviral protease.

E. Altmann, A. Bernardi, F. Sirockin, 2015, Bioorganic & medicinal chemistry letters.

From D -Camphor to the Taxanes. Highly Concise Rearrangement- Based Approaches to Taxusin and Taxol

S. Elmore, L. Paquette, Hui-Ling Wang, 1998 .

Respiratory syncytial virus fusion inhibitors. Part 4: optimization for oral bioavailability.

A. Marino, N. Meanwell, I. Medina, 2007, Bioorganic & medicinal chemistry letters.

New C25 carbamate rifamycin derivatives are resistant to inactivation by ADP-ribosyl transferases.

D. Yan, G. Robertson, E. Roche, 2007, Bioorganic & medicinal chemistry letters.

Oral Efficacy of a Respiratory Syncytial Virus Inhibitor in Rodent Models of Infection

N. Meanwell, I. Medina, C. Cianci, 2004, Antimicrobial Agents and Chemotherapy.

Orally Active Fusion Inhibitor of Respiratory Syncytial Virus

N. Meanwell, I. Medina, C. Cianci, 2004, Antimicrobial Agents and Chemotherapy.

Discovery and structure-based optimization of adenain inhibitors.

E. Altmann, A. Bernardi, F. Sirockin, 2014, ACS medicinal chemistry letters.

Respiratory syncytial virus fusion inhibitors. Part 7: structure-activity relationships associated with a series of isatin oximes that demonstrate antiviral activity in vivo.

A. Marino, N. Meanwell, I. Medina, 2009, Bioorganic & medicinal chemistry letters.

Therapeutic Opportunities for the Treatment of Biofilm-Associated Infections

T. Morris, Zhenkun Ma, K. Combrink, 2004 .

In vivo optimization of 2,3-diaminopyrazine Rho Kinase inhibitors for the treatment of glaucoma.

N. Sharif, Byron Li, I. Pang, 2014, Bioorganic & medicinal chemistry letters.

Salicylamide inhibitors of influenza virus fusion.

N. Meanwell, M. Deshpande, C. Cianci, 2000, Bioorganic & medicinal chemistry letters.

1,2-Benzisothiazol-3-one 1,1-dioxide inhibitors of human mast cell tryptase.

P. Stanley, N. Meanwell, B. Pearce, 1998, Journal of medicinal chemistry.

An Efficient Method for the Synthesis of 1-Arylalkynes

T. Engler, J. Ray, K. Combrink, 1989 .

Natural Dye-Sensitized Solar Cells: Fabrication, Characterization, and Challenges

D. Ganta, K. Combrink, R. Villanueva, 2018, Energy, Environment, and Sustainability.

Discovery and early clinical evaluation of BMS-605339, a potent and orally efficacious tripeptidic acylsulfonamide NS3 protease inhibitor for the treatment of hepatitis C virus infection.

A. Good, H. Klei, A. Cocuzza, 2014, Journal of medicinal chemistry.